Pandemic Risk Assessment Model (PRAM): a mathematical modeling approach to pandemic influenza planning

Epidemiology and Infection

Volumn 144, Issue 16, 2016, Pages 3400-3411

  Dover, D C ^a   Kirwin, E M ^a   Hernandez Ceron, N ^b   Nelson, K A ^c  

^a Analytics and Performance Reporting   (Canada)

^b PURDUE UNIVERSITY   (United States)

^c HEALTH CANADA   (Canada)

Author keywords

Influenza; mathematical modelling; pandemic; public health

Indexed keywords

ARTICLE; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DISEASE SURVEILLANCE; HUMAN; INFECTION CONTROL; INFECTION RISK; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PANDEMIC INFLUENZA; PANDEMIC RISK ASSESSMENT MODEL; PATIENT CARE; PUBLIC HEALTH; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 84983471926     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268816001850     Document Type: Article

References (71)

1. Last JM. A Dictionary of Epidemiology, 4th edn. New York: Oxford University Press; 2001.
2. Public Health Agency of Canada. The Management of the National Antiviral Stockpile: Options Report (http://www. phac-aspc. gc. ca/alert-alerte/h1n1/antivir/indexeng. php). Accessed 6 February 2015.
3. Biggerstaff M, et al. Estimating the potential effects of a vaccine program against an emerging influenza pandemic-United States. Clinical Infectious Diseases 2015; 60: S20-S29.
4. DoyleA, et al. Influenza pandemic preparedness inFrance: modelling the impact of interventions. Journal of Epidemiology and Community Health 2006; 60: 399-404.
5. Khazeni N, et al. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Annals of Internal Medicine 2009; 151: 840-853.
6. Khazeni N, et al. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Annals of Internal Medicine 2009; 151: 829-839.
7. O'Hagan JJ, et al. Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic. Clinical Infectious Diseases 2015; 60: S30-S41.
8. van Genugten ML, Heijnen MLA, Jager JC. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerging Infectious Diseases 2003; 9: 531-538.
9. Siddiqui M, Edmunds W. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerging Infectious Diseases 2008; 14: 267-274.
10. Alexander ME, et al. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proceedings of the Royal Society of London B: Biological Sciences 2007; 274: 1675-1684.
11. Alexander ME, et al. A delay differential model for pandemic influenza with antiviral treatment. Bulletin of mathematical biology 2008; 70: 382-397.
12. Arino J, Bowman CS, Moghadas SM. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. BMC Infectious Diseases. Published online: 22 Janurary 2009. doi: 10. 1186/1471-2334-9-8.
13. Baguelin M, et al. Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation. Vaccine 2010; 28: 2370-2384.
14. Bolton KJ, et al. Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control. PLoS ONE. Published online: 26 March 2015. doi: 10. 1371/journal. pone. 0120138.
15. Chowell G, et al. Adaptive vaccination strategies to mitigate pandemic influenza: Mexico as a case study. PLoS ONE. Published online: 3 December 2009. doi:10. 1371/ journal. pone. 0008164.
16. Fung ICH, et al. Modeling the Effect of SchoolClosures in a Pandemic Scenario: Exploring Two Different Contact Matrices. Clinical Infectious Diseases 2015; 60: S58-S63.
17. Ferguson NM, et al. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. Journal of Antimicrobial Chemotherapy 2003; 51: 977-990.
18. Greer AL, Schanzer D. Using a dynamic model to consider optimal antiviral stockpile size in the face of pandemic influenza uncertainty. PLoS ONE. Published online: 21 June 2013. doi: 10. 1371/journal. pone. 0067253.
19. Hansen E, et al. Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks. Canadian Journal of Infectious Diseases & Medical Microbiology 2010; 21: e28-e63.
20. Lee S, Chowell G, Castillo-Chávez C. Optimal control for pandemic influenza: The role of limited antiviral treatment and isolation. Journal of Theoretical Biology 2010; 265: 136-150.
21. Lipsitch M, et al. Antiviral resistance and the control of pandemic influenza. PLoS Medicine 2007; 4: 111-121.
22. McCaw JM, McVernon J. Prophylaxis or treatment Optimal use of an antiviral stockpile during an influenza pandemic. Mathematical Biosciences 2007; 209: 336-360.
23. Nuno M, Chowell G, Gumel AB. Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the Netherlands. Journal of the Royal Society Interface 2007; 4: 505-521.
24. Prosper O, et al. Modeling control strategies for concurrent epidemics of seasonal and pandemicH1N1influenza. Mathematical Biosciences and Engineering 2011; 8: 141-170.
25. Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006; 312: 389-391.
26. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. Journal of Infectious Diseases 1998; 177: 863-873.
27. Tuite AR, et al. Optimal pandemic influenza vaccine allocation strategies for the Canadian population. PLoS ONE. Published online: 12 April 2010. doi:10. 1371/ journal. pone. 0010520.
28. Zhang Q, Wang D. Antiviral prophylaxis and isolation for the control of pandemic influenza. International Journal of Environmental Research and Public Health 2014; 11: 7690-7712.
29. Gani R, et al. Potential impact of antiviral drug use during influenza pandemic. Emerging Infectious Diseases 2005; 11: 1355-1362.
30. Tuite A, et al. Seasonal vaccine allocation in the Canadian population during a pandemic. PLoSCurrents: Influenza. Published online: 11 December 2009. doi:10. 1371/currents. RRN1143.
31. Bansal S, et al. The shifting demographic landscape of pandemic influenza. PLoS ONE. Published online: 26 February 2010. doi:10. 1371/journal. pone. 0009360.
32. Germann TC, et al. Mitigation strategies for pandemic influenza in the United States. Proceedings of the NationalAcademy of SciencesUSA 2006; 103: 5935-5940.
33. Glass RJ, et al. Targeted social distancing design for pandemic influenza. Emerging Infectious Diseases 2006; 12: 1671-1681.
34. Halloran ME, et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proceedings of the National Academy of Sciences USA 2008; 105: 4639-4644.
35. Kramer SC, Bansal S. Assessing the use of antiviral treatment to control influenza. Epidemiology and Infection 2015; 143: 1621-1631.
36. Longini IM, et al. Containing pandemic influenza with antiviral agents. American Journal of Epidemiology 2014; 159: 623-633.
37. Longini IM, et al. Containing pandemic influenza at the source. Science 2005; 309: 1083-1087.
38. Milne GJ, et al. A small community model for the transmission of infectious diseases: comparison of school closure as an intervention in individual-based models of an influenza pandemic. PLoS ONE. Published online: 23 December 2008. doi:10. 1371/journal. pone. 0004005.
39. Sander B, et al. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value in Health 2009; 12: 226-233.
40. van den Dool C, et al. The effects of influenza vaccination of health care workers in nursing homes: insights from a mathematical model. PLoS Medicine. Published online: 28 October 2009. doi:10. 1371/journal. pmed. 0050200.
41. Wu JT, et al. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Medicine. Published online: 19 May 2009. doi:10. 1371/journal. pmed. 1000085.
42. Dimitrov NB, et al. Optimizing tactics for use of the U. S. Antiviral strategic national stockpile for pandemic influenza. PLoS ONE. Published online: 18 January 2011. doi:10. 1371/journal. pone. 0016094.
43. Lee VJ, Lye DC, Wilder-Smith A. Combination strategies for pandemic influenza response-a systematic review of mathematical modeling studies. BMC Medicine. Published online: 10 December 2009. doi:10. 1186/ 1741-7015-7-76.
44. Prieto DM, et al. A systematic review to identify areas of enhancements of pandemic simulation models for operational use at provincial and local levels. BMC Public Health. Published online: 30 March 2012. doi:10. 1186/ 1471-2458-12-251.
45. Reed C, et al. Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics. Emerging Infectious Diseases 2013; 19: 85-91.
46. Riley P, et al. Early characterization of the severity and transmissibility of pandemic influenza using clinical episode data from multiple populations. PLoS Computational Biology. Published online: 24 September 2015. doi: 10. 1371/journal. pcbi. 1004392.
47. World Health Organization. Pandemic influenza risk management: WHO interim guidance, 2013.
48. Ogunjimi B, et al. Using empirical social contact data to model person to person infectious disease transmission: An illustration for varicella. Mathematical Biosciences 2009; 218: 80-87.
49. Mossong J, et al. Social contacts andmixing patterns relevant to the spread of infectious diseases. PLoS Medicine. Published online: 25 March 2008. doi:10. 1371/journal. pmed. 0050074.
50. Aho M, et al. Outbreak of 2009 pandemic influenza A (H1N1) in a Finnish garrison-a serological survey. Eurosurveillance, 2010; 15, 19709.
51. Papenburg J, et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratoryconfirmed secondary attack rates and evidence of asymptomatic infections. Clinical Infectious Diseases, 2010; 51: 1033-1041.
52. Leung NHL, Xu C, Ip DKM, Cowling BJ. The fraction of influenza virus infections that are asymptomatic: A systematic review and meta-analysis. Epidemiology. Published online: 24 May 2015. doi:10. 1097/EDE. 0000000000000340.
53. Diekmann O, Heesterbeek JAP, Metz JAJ. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology 1990; 28: 365-382.
54. Van Den Driessche P, Watmough J. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Mathematical Biosciences, 2002; 180: 29-48.
55. Miller MR, et al. Predictors of influenza diagnosis among patients with laboratory-confirmed influenza. Journal of Infectious Diseases 2015; 212: 1604-1612.
56. Government of Alberta. Pandemic (H1N1) 2009: The Alberta experience (http://www. Albertahealthservices. ca/ poph/hi-poph-surv-h1n1-ab-experience-2009. pdf). Accessed 6 February 2015.
57. Sikora C, et al. Transmission of pandemic influenza A (H1N1) 2009 within households: Edmonton, Canada. Journal of Clinical Virology, 2010; 49: 90-93.
58. Osterholm MT, et al. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet 2012; 12: 36-44.
59. Tuite AR, et al. Estimated epidemiologic parameters and morbidity associated with pandemic h1n1 influenza. CanadianMedicalAssociation Journal 2010; 182: 131-136.
60. Chowell G, Miller MA, Viboud C. Seasonal influenza in the United States, France, and Australia: Transmission and prospects for control. Epidemiological Infection 2008; 136: 852-864.
61. Carrat F, et al. Time lines of infection and disease in human influenza: A review of volunteer challenge studies. American Journal of Epidemiology 2008; 167: 775-785
62. Killingley B, et al. Virus shedding and environmental deposition of novel A(H1N1) pandemic influenza virus: interim findings. Health Technology Assessment 2010; 14: 237-354.
63. Suess T, et al. Shedding and transmission of novel influenza virus A/H1N1 infection in households-Germany, 2009. American journal of epidemiology 2010; 171: 1157-1164.
64. Cao B, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. New England Journal of Medicine 2009; 361: 2507-2517.
65. Li IW, et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest Journal 2010; 137: 759-768.
66. Ling LM, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clinical Infectious Diseases 2010; 50: 963-969.
67. Chen Y, et al. Risk factors for prolonged shedding of 2009 H1N1influenza virus. IndianPediatrics 2011; 48: 961-963.
68. Meschi S, et al. Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infectious Diseases. Published online: 23 May 2011. doi:10. 1186/1471-2334-11-140.
69. Na S, et al. Duration of viral shedding in patients admitted to hospital with pandemic influenza A/H1N1 2009 infection. Journal of Medical Virology 2011; 83: 5-9.
70. Siau C, et al. Influenza A H1N1 (2009): clinical spectrum of disease among adult patients admitted to a regional hospital in Singapore. Singapore Medical Journal 2011; 52: 475-480.
71. Biggerstaff M, et al. Estimates of the reproduction number for seasonal, pandemic and zoonotic influenza: A systemic review of the literature. BMC Infectious Diseases. Published online: 4 September 2014. doi: 10. 1186/1471-2334-14-480.